Leydig cell tumors: Prognostic factors

Abstract

Leydig Cell Tumors (LCT) are uncommon testicular neoplasms that account for 1 to 3% of all testicular tumors. Only about 10% of LCT are malignant and generally refractory to radiotherapy and conventional chemotherapy. Therefore, there is some debate about the value of Retroperitoneal Lymphadenectomy (RPLND) in Stage I disease. Indeed, although surgery is the only available therapy which is able to cure and prevent tumor spread, RPLND is a challenging invasive surgery and may be useless in 90% of the cases. The Authors observed 5 cases of patients in clinical Stage I disease with benign behaviour demonstrated after an adequate follow-up. Pathological analysis showed absence of signs of malignancy. Starting from these experiences, it is suggested that RPLND may be avoided in selected cases when definite pathological signs of malignancy are absent.